Immune modulatory therapies for spinal cord injury - Past, present and future

Experimental Neurology

Volumn 258, Issue , 2014, Pages 91-104

  Plemel, Jason R ^a   Wee Yong, V ^a   Stirling, David P ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Gr 1; Ly 6C; Ly 6G; M1; M2; Macrophage; Microglia; Minocycline; Neuroinflammation; Neuroprotection; Neutrophil; Spinal cord injury

Indexed keywords

CD11D ANTIBODY; CELL ANTIGEN; GRANULOCYTE DIFFERENTIATION ANTIGEN 1; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MINOCYCLINE; MONOCLONAL ANTIBODY; STEROID; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

CELL FUNCTION; CELL SUBPOPULATION; CELL THERAPY; CELLULAR DISTRIBUTION; DRUG RESPONSE; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NERVE FIBER REGENERATION; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; SPINAL CORD INJURY; SUPPRESSOR CELL; ANIMAL; DRUG EFFECT; FORECASTING; GR-1; IMMUNOLOGY; LY-6C; LY-6G; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; PATHOLOGY;

GR-1; LY-6C; LY-6G; MACROPHAGE; MICROGLIA; MINOCYCLINE; NEUROINFLAMMATION; NEUROPROTECTION; NEUTROPHIL; SPINAL CORD INJURY;

ANIMALS; FORECASTING; HUMANS; IMMUNOLOGIC FACTORS; MACROPHAGES; MICROGLIA; SPINAL CORD INJURIES;

EID: 84904807684     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.01.025     Document Type: Review

References (232)

1. Allan S.M., Rothwell N.J. Inflammation in central nervous system injury. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:1669-1677.
2. Allison A.C., Harington J.S., Birbeck M. An examination of the cytotoxic effects of silica on macrophages. J. Exp. Med. 1966, 124:141-154.
3. Ankeny D.P., Guan Z., Popovich P.G. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J. Clin. Invest. 2009, 119:2990-2999.
4. Ankeny D.P., Lucin K.M., Sanders V.M., McGaughy V.M., Popovich P.G. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J. Neurochem. 2006, 99:1073-1087.
5. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., Harley J.B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 2003, 349:1526-1533.
6. Bao F., Chen Y., Dekaban G.A., Weaver L.C. An anti-CD11d integrin antibody reduces cyclooxygenase-2 expression and protein and DNA oxidation after spinal cord injury in rats. J. Neurochem. 2004, 90:1194-1204.
7. Bao F., Chen Y., Dekaban G.A., Weaver L.C. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. J. Neurochem. 2004, 88:1335-1344.
8. Bao F., Dekaban G.A., Weaver L.C. Anti-CD11d antibody treatment reduces free radical formation and cell death in the injured spinal cord of rats. J. Neurochem. 2005, 94:1361-1373.
9. Bao F., Liu D. Hydroxyl radicals generated in the rat spinal cord at the level produced by impact injury induce cell death by necrosis and apoptosis: protection by a metalloporphyrin. Neuroscience 2004, 126:285-295.
10. Baptiste D.C., Fehlings M.G. Emerging drugs for spinal cord injury. Expert Opin. Emerg. Drugs 2008, 13:63-80.
11. Barrette B., Hebert M.A., Filali M., Lafortune K., Vallieres N., Gowing G., Julien J.P., Lacroix S. Requirement of myeloid cells for axon regeneration. J. Neurosci. 2008, 28:9363-9376.
12. Bartholdi D., Schwab M.E. Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res. 1995, 672:177-186.
13. Beck K.D., Nguyen H.X., Galvan M.D., Salazar D.L., WoodruffT.M., Anderson A.J. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 2010, 133:433-447.
14. Berg J.T., Lee S.T., Thepen T., Lee C.Y., Tsan M.F. Depletion of alveolar macrophages by liposome-encapsulated dichloromethylene diphosphonate. J. Appl. Physiol. 1993, 74:2812-2819.
15. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 2003, 349:139-145.
16. Beuche W., Friede R.L. Myelin phagocytosis in Wallerian degeneration of peripheral nerves depends on silica-sensitive, bg/bg-negative and Fc-positive monocytes. Brain Res. 1986, 378:97-106.
17. Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 1993, 11:767-804.
18. Blight A.R. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent. Nerv. Syst. Trauma 1985, 2:299-315.
19. Blight A.R. Effects of silica on the outcome from experimental spinal cord injury: implication of macrophages in secondary tissue damage. Neuroscience 1994, 60:263-273.
20. Blight A.R., Cohen T.I., Saito K., Heyes M.P. Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain 1995, 118(Pt 3):735-752.
21. Bomstein Y., Marder J.B., Vitner K., Smirnov I., Lisaey G., Butovsky O., Fulga V., Yoles E. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J. Neuroimmunol. 2003, 142:10-16.
22. Bracken M.B. Steroids for acute spinal cord injury. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD001046. http://dx.doi.org/10.1002/14651858.CD001046.pub2.
23. Bracken M.B., Collins W.F., Freeman D.F., Shepard M.J., Wagner F.W., Silten R.M., Hellenbrand K.G., RansohoffJ., Hunt W.E., Perot P.L., et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984, 251:45-52.
24. Bracken M.B., Holford T.R. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J. Neurosurg. 1993, 79:500-507.
25. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J., et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 1990, 322:1405-1411.
26. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J.C., Marshall L.F., et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J. Neurosurg. 1992, 76:23-31.
27. Bracken M.B., Shepard M.J., Hellenbrand K.G., Collins W.F., Leo L.S., Freeman D.F., Wagner F.C., Flamm E.S., Eisenberg H.M., Goodman J.H., et al. Methylprednisolone and neurological function 1year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J. Neurosurg. 1985, 63:704-713.
28. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Administration of methylprednisolone for 24 or 48hours or tirilazad mesylate for 48hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277:1597-1604.
29. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M.G., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J. Neurosurg. 1998, 89:699-706.
30. +)-ATPase, lipid peroxidation, and alpha motor neuron function. J. Neurosurg. 1982, 56:838-844.
31. Carlson S.L., Parrish M.E., Springer J.E., Doty K., Dossett L. Acute inflammatory response in spinal cord following impact injury. Exp. Neurol. 1998, 151:77-88.
32. Casha S., Zygun D., McGowan M.D., Bains I., Yong V.W., Hurlbert R.J. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 2012, 135:1224-1236.
33. Cen L.P., Luo J.M., Zhang C.W., Fan Y.M., Song Y., So K.F., van Rooijen N., Pang C.P., Lam D.S., Cui Q. Chemotactic effect of ciliary neurotrophic factor on macrophages in retinal ganglion cell survival and axonal regeneration. Invest. Ophthalmol. Vis. Sci. 2007, 48:4257-4266.
34. Chen Q., Shine H.D. Neuroimmune processes associated with Wallerian degeneration support neurotrophin-3-induced axonal sprouting in the injured spinal cord. J. Neurosci. Res. 2013, 91:1280-1291.
35. Chikuda H., Yasunaga H., Takeshita K., Horiguchi H., Kawaguchi H., Ohe K., Fushimi K., Tanaka S. Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: a propensity-matched analysis using a nationwide administrative database. Emerg. Med. J. 2014, 31:201-206.
36. clinicaltrials.gov Minocycline in Acute Spinal Cord Injury (MASC) 2013.
37. Coffey P.J., Perry V.H., Allen Y., Sinden J., Rawlins J.N. Ibotenic acid induced demyelination in the central nervous system: a consequence of a local inflammatory response. Neurosci. Lett. 1988, 84:178-184.
38. Coleman W.P., Benzel D., Cahill D.W., Ducker T., Geisler F., Green B., Gropper M.R., Goffin J., Madsen P.W., Maiman D.J., Ondra S.L., Rosner M., Sasso R.C., Trost G.R., Zeidman S. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J. Spinal Disord. 2000, 13:185-199.
39. Conlan J.W., North R.J. Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J. Exp. Med. 1994, 179:259-268.
40. Coutinho A.E., Chapman K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 2011, 335:2-13.
41. Cuartero M.I., Ballesteros I., Moraga A., Nombela F., Vivancos J., Hamilton J.A., Corbi A.L., Lizasoain I., Moro M.A. N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARgamma agonist rosiglitazone. Stroke 2013, 44:3498-3508.
42. Dalakas M.C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002, 59:S13-S21.
43. David S., Lopez-Vales R., Wee Yong V. Harmful and beneficial effects of inflammation after spinal cord injury: potential therapeutic implications. Handb. Clin. Neurol. 2012, 109:485-502.
44. De Bosscher K., Vanden Berghe W., Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 2003, 24:488-522.
45. de Castro R., Hughes M.G., Xu G.Y., Clifton C., Calingasan N.Y., Gelman B.B., McAdoo D.J. Evidence that infiltrating neutrophils do not release reactive oxygen species in the site of spinal cord injury. Exp. Neurol. 2004, 190:414-424.
46. del Zoppo G.J. Acute anti-inflammatory approaches to ischemic stroke. Ann. N. Y. Acad. Sci. 2010, 1207:143-148.
47. Dibaj P., Nadrigny F., Steffens H., Scheller A., Hirrlinger J., Schomburg E.D., Neusch C., KirchhoffF. NO mediates microglial response to acute spinal cord injury under ATP control in vivo. Glia 2010, 58:1133-1144.
48. Ditor D.S., Bao F., Chen Y., Dekaban G.A., Weaver L.C. A therapeutic time window for anti-CD 11d monoclonal antibody treatment yielding reduced secondary tissue damage and enhanced behavioral recovery following severe spinal cord injury. J. Neurosurg. Spine 2006, 5:343-352.
49. Domeniconi M., Cao Z., Spencer T., Sivasankaran R., Wang K., Nikulina E., Kimura N., Cai H., Deng K., Gao Y., He Z., Filbin M. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 2002, 35:283-290.
50. Donnelly D.J., Longbrake E.E., Shawler T.M., Kigerl K.A., Lai W., Tovar C.A., RansohoffR.M., Popovich P.G. Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J. Neurosci. 2011, 31:9910-9922.
51. Durandy A., Kaveri S.V., Kuijpers T.W., Basta M., Miescher S., Ravetch J.V., Rieben R. Intravenous immunoglobulins-understanding properties and mechanisms. Clin. Exp. Immunol. 2009, 158(Suppl. 1):2-13.
52. Dusart I., Schwab M.E. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci. 1994, 6:712-724.
53. Easton A.S. Neutrophils and stroke - can neutrophils mitigate disease in the central nervous system?. Int Immunopharmacol 2013, 17(4):1218-1225. 10.1016/j.intimp.2013.06.015.
54. Edwards P., Arango M., Balica L., Cottingham R., El-Sayed H., Farrell B., Fernandes J., Gogichaisvili T., Golden N., Hartzenberg B., Husain M., Ulloa M.I., Jerbi Z., Khamis H., Komolafe E., Laloe V., Lomas G., Ludwig S., Mazairac G., Munoz Sanchez Mde L., Nasi L., Olldashi F., Plunkett P., Roberts I., Sandercock P., Shakur H., Soler C., Stocker R., Svoboda P., Trenkler S., Venkataramana N.K., Wasserberg J., Yates D., Yutthakasemsunt S. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6months. Lancet 2005, 365:1957-1959. Collaborators, C. T.
55. Enlimomab Acute Stroke Trial I. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001, 57:1428-1434.
56. Farooque M., Isaksson J., Olsson Y. Improved recovery after spinal cord trauma in ICAM-1 and P-selectin knockout mice. Neuroreport 1999, 10:131-134.
57. Farooque M., Isaksson J., Olsson Y. White matter preservation after spinal cord injury in ICAM-1/P-selectin-deficient mice. Acta Neuropathol. 2001, 102:132-140.
58. Faulkner J.R., Herrmann J.E., Woo M.J., Tansey K.E., Doan N.B., Sofroniew M.V. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 2004, 24:2143-2155.
59. Fehlings M.G., Nguyen D.H. Immunoglobulin G: a potential treatment to attenuate neuroinflammation following spinal cord injury. J. Clin. Immunol. 2010, 30(Suppl. 1):S109-S112.
60. FestoffB.W., Ameenuddin S., Arnold P.M., Wong A., Santacruz K.S., Citron B.A. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J. Neurochem. 2006, 97:1314-1326.
61. Filbin M.T. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci. 2003, 4:703-713.
62. Fischer D., Hauk T.G., Muller A., Thanos S. Crystallins of the beta/gamma-superfamily mimic the effects of lens injury and promote axon regeneration. Mol. Cell. Neurosci. 2008, 37:471-479.
63. Fischer D., Pavlidis M., Thanos S. Cataractogenic lens injury prevents traumatic ganglion cell death and promotes axonal regeneration both in vivo and in culture. Invest. Ophthalmol. Vis. Sci. 2000, 41:3943-3954.
64. Fitch M.T., Doller C., Combs C.K., Landreth G.E., Silver J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J. Neurosci. 1999, 19:8182-8198.
65. Fleming J.C., Norenberg M.D., Ramsay D.A., Dekaban G.A., Marcillo A.E., Saenz A.D., Pasquale-Styles M., Dietrich W.D., Weaver L.C. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269.
66. Fleming T.J., Fleming M.L., Malek T.R. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 1993, 151:2399-2408.
67. Foote A.K., Blakemore W.F. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 2005, 128:528-539.
68. Franzen R., Schoenen J., Leprince P., Joosten E., Moonen G., Martin D. Effects of macrophage transplantation in the injured adult rat spinal cord: a combined immunocytochemical and biochemical study. J. Neurosci. Res. 1998, 51:316-327.
69. Furlan J.C., Krassioukov A.V., Fehlings M.G. Hematologic abnormalities within the first week after acute isolated traumatic cervical spinal cord injury: a case-control cohort study. Spine (Phila Pa 1976) 2006, 31:2674-2683.
70. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
71. Geissmann F., Auffray C., Palframan R., Wirrig C., Ciocca A., Campisi L., Narni-Mancinelli E., Lauvau G. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol. Cell Biol. 2008, 86:398-408.
72. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
73. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999, 5:170-175.
74. Gensel J.C., Nakamura S., Guan Z., van Rooijen N., Ankeny D.P., Popovich P.G. Macrophages promote axon regeneration with concurrent neurotoxicity. J. Neurosci. 2009, 29:3956-3968.
75. Giulian D., Li J., Leara B., Keenen C. Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture. Neurochem. Int. 1994, 25:227-233.
76. Gok B., Sciubba D.M., Okutan O., Beskonakli E., Palaoglu S., Erdamar H., Sargon M.F. Immunomodulation of acute experimental spinal cord injury with human immunoglobulin G. J. Clin. Neurosci. 2009, 16:549-553.
77. Gonzalez R., Glaser J., Liu M.T., Lane T.E., Keirstead H.S. Reducing inflammation decreases secondary degeneration and functional deficit after spinal cord injury. Exp. Neurol. 2003, 184:456-463.
78. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
79. Gris D., Marsh D.R., Dekaban G.A., Weaver L.C. Comparison of effects of methylprednisolone and anti-CD11d antibody treatments on autonomic dysreflexia after spinal cord injury. Exp. Neurol. 2005, 194:541-549.
80. Gris D., Marsh D.R., Oatway M.A., Chen Y., Hamilton E.F., Dekaban G.A., Weaver L.C. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J. Neurosci. 2004, 24:4043-4051.
81. Gris P., Tighe A., Thawer S., Hemphill A., Oatway M., Weaver L., Dekaban G.A., Brown A. Gene expression profiling in anti-CD11d mAb-treated spinal cord-injured rats. J. Neuroimmunol. 2009, 209:104-113.
82. Ha K.Y., Kim Y.H., Rhyu K.W., Kwon S.E. Pregabalin as a neuroprotector after spinal cord injury in rats. Eur. Spine J. 2008, 17:864-872.
83. Hall E.D., Braughler J.M. Acute effects of intravenous glucocorticoid pretreatment on the in vitro peroxidation of cat spinal cord tissue. Exp. Neurol. 1981, 73:321-324.
84. Hall E.D., Springer J.E. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004, 1:80-100.
85. Hamada Y., Ikata T., Katoh S., Nakauchi K., Niwa M., Kawai Y., Fukuzawa K. Involvement of an intercellular adhesion molecule 1-dependent pathway in the pathogenesis of secondary changes after spinal cord injury in rats. J. Neurochem. 1996, 66:1525-1531.
86. Harlan J.M. Consequences of leukocyte-vessel wall interactions in inflammatory and immune reactions. Semin. Thromb. Hemost. 1987, 13:434-444.
87. Harlan J.M., Winn R.K. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit. Care Med. 2002, 30:S214-S219.
88. Hauben E., Agranov E., Gothilf A., Nevo U., Cohen A., Smirnov I., Steinman L., Schwartz M. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 2001, 108:591-599.
89. Hauben E., Butovsky O., Nevo U., Yoles E., Moalem G., Agranov E., Mor F., Leibowitz-Amit R., Pevsner E., Akselrod S., Neeman M., Cohen I.R., Schwartz M. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 2000, 20:6421-6430.
90. Hauben E., Nevo U., Yoles E., Moalem G., Agranov E., Mor F., Akselrod S., Neeman M., Cohen I.R., Schwartz M. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet 2000, 355:286-287.
91. Hauk T.G., Leibinger M., Muller A., Andreadaki A., Knippschild U., Fischer D. Stimulation of axon regeneration in the mature optic nerve by intravitreal application of the toll-like receptor 2 agonist Pam3Cys. Invest. Ophthalmol. Vis. Sci. 2010, 51:459-464.
92. Hawthorne A.L., Popovich P.G. Emerging concepts in myeloid cell biology after spinal cord injury. Neurotherapeutics 2011, 8:252-261.
93. Hayes K.C., Hull T.C., Delaney G.A., Potter P.J., Sequeira K.A., Campbell K., Popovich P.G. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J. Neurotrauma 2002, 19:753-761.
94. Hestdal K., Ruscetti F.W., Ihle J.N., Jacobsen S.E., Dubois C.M., Kopp W.C., Longo D.L., Keller J.R. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 1991, 147:22-28.
95. Higashiyama M., Hokari R., Matsunaga H., Takebayashi K., Watanabe C., Komoto S., Okada Y., Kurihara C., Kawaguchi A., Nagao S., Itoh K., Miura S. P-selectin-dependent monocyte recruitment through platelet interaction in intestinal microvessels of LPS-treated mice. Microcirculation 2008, 15:441-450.
96. Holtz A., Nystrom B., Gerdin B. Spinal cord injury in rats: inability of nimodipine or anti-neutrophil serum to improve spinal cord blood flow or neurologic status. Acta Neurol. Scand. 1989, 79:460-467.
97. Horn K.P., Busch S.A., Hawthorne A.L., van Rooijen N., Silver J. Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions. J. Neurosci. 2008, 28:9330-9341.
98. Hsu C.Y., Dimitrijevic M.R. Methylprednisolone in spinal cord injury: the possible mechanism of action. J. Neurotrauma 1990, 7:115-119.
99. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
100. Hughes R.A., Dalakas M.C., Cornblath D.R., Latov N., Weksler M.E., Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin. Exp. Immunol. 2009, 158(Suppl. 1):34-42.
101. Huitinga I., Damoiseaux J.G., van Rooijen N., Dopp E.A., Dijkstra C.D. Liposome mediated affection of monocytes. Immunobiology 1992, 185:11-19.
102. Hurlbert R.J. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J. Neurosurg. 2000, 93:1-7.
103. Hurlbert R.J., Hamilton M.G. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can. J. Neurol. Sci. 2008, 35:41-45.
104. Hurtado A., Marcillo A., Frydel B., Bunge M.B., Bramlett H.M., Dietrich W.D. Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury. Exp. Neurol. 2012, 233:606-611.
105. Iannotti C.A., Clark M., Horn K.P., van Rooijen N., Silver J., Steinmetz M.P. A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI. Exp. Neurol. 2011, 230:3-15.
106. Ibarra A., Hauben E., Butovsky O., Schwartz M. The therapeutic window after spinal cord injury can accommodate T cell-based vaccination and methylprednisolone in rats. Eur. J. Neurosci. 2004, 19:2984-2990.
107. Ishii H., Jin X., Ueno M., Tanabe S., Kubo T., Serada S., Naka T., Yamashita T. Adoptive transfer of Th1-conditioned lymphocytes promotes axonal remodeling and functional recovery after spinal cord injury. Cell Death Dis 2012, 3:e363.
108. Jones L.A., Lammertse D.P., Charlifue S.B., Kirshblum S.C., Apple D.F., Ragnarsson K.T., Poonian D., Betz R.R., Knoller N., Heary R.F., Choudhri T.F., Jenkins A.L., Falci S.P., Snyder D.A. A phase 2 autologous cellular therapy trial in patients with acute, complete spinal cord injury: pragmatics, recruitment, and demographics. Spinal Cord 2010, 48:798-807.
109. Jones T.B. Lymphocytes and autoimmunity after spinal cord injury. Exp. Neurol. 2014, 258:78-90. (in this issue).
110. Jones T.B., Ankeny D.P., Guan Z., McGaughy V., Fisher L.C., Basso D.M., Popovich P.G. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J. Neurosci. 2004, 24:3752-3761.
111. Jones T.B., Basso D.M., Sodhi A., Pan J.Z., Hart R.P., MacCallum R.C., Lee S., Whitacre C.C., Popovich P.G. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J. Neurosci. 2002, 22:2690-2700.
112. Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 2009, 29:13435-13444.
113. Kigerl K.A., McGaughy V.M., Popovich P.G. Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. J. Comp. Neurol. 2006, 494:578-594.
114. Kil K., Zang Y.C., Yang D., Markowski J., Fuoco G.S., Vendetti G.C., Rivera V.M., Zhang J.Z. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J. Neuroimmunol. 1999, 98:201-207.
115. Kim J.V., Kang S.S., Dustin M.L., McGavern D.B. Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis. Nature 2009, 457:191-195.
116. Kim S.S., Kong P.J., Kim B.S., Sheen D.H., Nam S.Y., Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch. Pharm. Res. 2004, 27:314-318.
117. Kipnis J., Mizrahi T., Hauben E., Shaked I., Shevach E., Schwartz M. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15620-15625.
118. Klegeris A., McGeer P.L. Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. J. Neuroimmunol. 1994, 53:83-90.
119. Knoller N., Auerbach G., Fulga V., Zelig G., Attias J., Bakimer R., Marder J.B., Yoles E., Belkin M., Schwartz M., Hadani M. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J. Neurosurg. Spine 2005, 3:173-181.
120. Kobayashi K., Imagama S., Ohgomori T., Hirano K., Uchimura K., Sakamoto K., Hirakawa A., Takeuchi H., Suzumura A., Ishiguro N., Kadomatsu K. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 2013, 4:e525.
121. Kotter M.R., Setzu A., Sim F.J., Van Rooijen N., Franklin R.J. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001, 35:204-212.
122. Kotter M.R., Zhao C., van Rooijen N., Franklin R.J. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol. Dis. 2005, 18:166-175.
123. Kowal C., DeGiorgio L.A., Nakaoka T., Hetherington H., Huerta P.T., Diamond B., Volpe B.T. Cognition and immunity; antibody impairs memory. Immunity 2004, 21:179-188.
124. Krams M., Lees K.R., Hacke W., Grieve A.P., Orgogozo J.M., Ford G.A., Investigators A.S. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003, 34:2543-2548.
125. Kremlev S.G., Roberts R.L., Palmer C. Differential expression of chemokines and chemokine receptors during microglial activation and inhibition. J. Neuroimmunol. 2004, 149:1-9.
126. Kubeck J.P., Merola A., Mathur S., Brkaric M., Majid K., Shanti N., Caruso S., Yuan S., Lowe T., Dwyer A., Haher T., O'Brien M. End organ effects of high-dose human equivalent methylprednisolone in a spinal cord injury rat model. Spine (Phila Pa 1976) 2006, 31:257-261.
127. Kurimoto T., Yin Y., Habboub G., Gilbert H.Y., Li Y., Nakao S., Hafezi-Moghadam A., Benowitz L.I. Neutrophils express oncomodulin and promote optic nerve regeneration. J. Neurosci. 2013, 33:14816-14824.
128. Kwon B.K., Okon E., Hillyer J., Mann C., Baptiste D., Weaver L.C., Fehlings M.G., TetzlaffW. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J. Neurotrauma 2011, 28:1545-1588.
129. Kwon B.K., Okon E.B., Tsai E., Beattie M.S., Bresnahan J.C., Magnuson D.K., Reier P.J., McTigue D.M., Popovich P.G., Blight A.R., Oudega M., Guest J.D., Weaver L.C., Fehlings M.G., TetzlaffW. A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury. J. Neurotrauma 2011, 28:1525-1543.
130. Lammertse D.P., Jones L.A., Charlifue S.B., Kirshblum S.C., Apple D.F., Ragnarsson K.T., Falci S.P., Heary R.F., Choudhri T.F., Jenkins A.L., Betz R.R., Poonian D., Cuthbert J.P., Jha A., Snyder D.A., Knoller N. Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord 2012, 50:661-671.
131. Lazarov-Spiegler O., Solomon A.S., Zeev-Brann A.B., Hirschberg D.L., Lavie V., Schwartz M. Transplantation of activated macrophages overcomes central nervous system regrowth failure. Faseb J 1996, 10:1296-1302.
132. Lee J.H., Tigchelaar S., Liu J., Stammers A.M., Streijger F., TetzlaffW., Kwon B.K. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury. Exp. Neurol. 2010, 225:219-230.
133. Lee P.Y., Wang J.X., Parisini E., Dascher C.C., Nigrovic P.A. Ly6 family proteins in neutrophil biology. J. Leukoc. Biol. 2013, 94:585-594.
134. Lee S.M., Rosen S., Weinstein P., van Rooijen N., Noble-Haeusslein L.J. Prevention of both neutrophil and monocyte recruitment promotes recovery after spinal cord injury. J. Neurotrauma 2011, 28:1893-1907.
135. Lee S.M., Yune T.Y., Kim S.J., Kim Y.C., Oh Y.J., Markelonis G.J., Oh T.H. Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J. Neurochem. 2004, 91:568-578.
136. Lee S.M., Yune T.Y., Kim S.J., Park D.W., Lee Y.K., Kim Y.C., Oh Y.J., Markelonis G.J., Oh T.H. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J. Neurotrauma 2003, 20:1017-1027.
137. Legos J.J., Gopez J.J., Young W.F. Non-surgical management of spinal cord injury. Expert Opin. Investig. Drugs 2002, 11:469-482.
138. Leibinger M., Muller A., Andreadaki A., Hauk T.G., Kirsch M., Fischer D. Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J. Neurosci. 2009, 29:14334-14341.
139. Leon S., Yin Y., Nguyen J., Irwin N., Benowitz L.I. Lens injury stimulates axon regeneration in the mature rat optic nerve. J. Neurosci. 2000, 20:4615-4626.
140. Liao Y., Liu P., Guo F., Zhang Z.Y., Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. PLoS One 2013, 8:e68963.
141. Liu D., Sybert T.E., Qian H., Liu J. Superoxide production after spinal injury detected by microperfusion of cytochrome c. Free Radic. Biol. Med. 1998, 25:298-304.
142. Luchetti S., Beck K.D., Galvan M.D., Silva R., Cummings B.J., Anderson A.J. Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury. J. Neurotrauma 2010, 27:411-421.
143. Lucin K.M., Sanders V.M., Popovich P.G. Stress hormones collaborate to induce lymphocyte apoptosis after high level spinal cord injury. J. Neurochem. 2009, 110:1409-1421.
144. Mabon P.J., Weaver L.C., Dekaban G.A. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 2000, 166:52-64.
145. McKay L.I., Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev. 1999, 20:435-459.
146. Means E.D., Anderson D.K. Neuronophagia by leukocytes in experimental spinal cord injury. J. Neuropathol. Exp. Neurol. 1983, 42:707-719.
147. Meisel C., Schwab J.M., Prass K., Meisel A., Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat. Rev. Neurosci. 2005, 6:775-786.
148. Miller S.M. Methylprednisolone in acute spinal cord injury: a tarnished standard. J. Neurosurg. Anesthesiol. 2008, 20:140-142.
149. Miron V.E., Boyd A., Zhao J.W., Yuen T.J., Ruckh J.M., Shadrach J.L., van Wijngaarden P., Wagers A.J., Williams A., Franklin R.J., Ffrench-Constant C. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 2013, 16:1211-1218.
150. Mizrachi Y., Ohry A., Aviel A., Rozin R., Brooks M.E., Schwartz M. Systemic humoral factors participating in the course of spinal cord injury. Paraplegia 1983, 21:287-293.
151. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., De Baetselier P., Van Ginderachter J.A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
152. Mukhopadhyay G., Doherty P., Walsh F.S., Crocker P.R., Filbin M.T. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994, 13:757-767.
153. Muller A., Hauk T.G., Leibinger M., Marienfeld R., Fischer D. Exogenous CNTF stimulates axon regeneration of retinal ganglion cells partially via endogenous CNTF. Mol. Cell. Neurosci. 2009, 41:233-246.
154. Nagendra S., Schlueter A.J. Absence of cross-reactivity between murine Ly-6C and Ly-6G. Cytometry A 2004, 58:195-200.
155. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 2006, 6:173-182.
156. Nguyen D.H., Cho N., Satkunendrarajah K., Austin J.W., Wang J., Fehlings M.G. Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury. J. Neuroinflammation 2012, 9:224.
157. Nikic I., Merkler D., Sorbara C., Brinkoetter M., Kreutzfeldt M., Bareyre F.M., Bruck W., Bishop D., Misgeld T., Kerschensteiner M. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 2011, 17:495-499.
158. Oatway M.A., Chen Y., Bruce J.C., Dekaban G.A., Weaver L.C. Anti-CD11d integrin antibody treatment restores normal serotonergic projections to the dorsal, intermediate, and ventral horns of the injured spinal cord. J. Neurosci. 2005, 25:637-647.
159. Okada S., Nakamura M., Katoh H., Miyao T., Shimazaki T., Ishii K., Yamane J., Yoshimura A., Iwamoto Y., Toyama Y., Okano H. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat. Med. 2006, 12:829-834.
160. Oudega M., Vargas C.G., Weber A.B., Kleitman N., Bunge M.B. Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur. J. Neurosci. 1999, 11:2453-2464.
161. Park E.J., Park K. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol. Lett. 2009, 184:18-25.
162. Pearsall N.N., Weiser R.S. The macrophage in allograft immunity. I. Effects of silica as a specific macrophage toxin. J. Reticuloendothel. Soc. 1968, 5:107-120.
163. Pineau I., Sun L., Bastien D., Lacroix S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain Behav. Immun. 2010, 24:540-553.
164. Pinzon A., Marcillo A., Quintana A., Stamler S., Bunge M.B., Bramlett H.M., Dietrich W.D. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res. 2008, 1243:146-151.
165. Popovich P.G., Guan Z., McGaughy V., Fisher L., Hickey W.F., Basso D.M. The neuropathological and behavioral consequences of intraspinal microglial/macrophage activation. J. Neuropathol. Exp. Neurol. 2002, 61:623-633.
166. Popovich P.G., Guan Z., Wei P., Huitinga I., van Rooijen N., Stokes B.T. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp. Neurol. 1999, 158:351-365.
167. Popovich P.G., Wei P., Stokes B.T. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 1997, 377:443-464.
168. Prewitt C.M., Niesman I.R., Kane C.J., Houle J.D. Activated macrophage/microglial cells can promote the regeneration of sensory axons into the injured spinal cord. Exp. Neurol. 1997, 148:433-443.
169. Qian Q., Jutila M.A., Van Rooijen N., Cutler J.E. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J. Immunol. 1994, 152:5000-5008.
170. Qizilbash N., Lewington S.L., Lopez-Arrieta J.M. Corticosteroids for acute ischaemic stroke. Cochrane Database Syst. Rev. 2002, CD000064.
171. Rabchevsky A.G., Streit W.J. Grafting of cultured microglial cells into the lesioned spinal cord of adult rats enhances neurite outgrowth. J. Neurosci. Res. 1997, 47:34-48.
172. Radi Z.A., Kehrli M.E., Ackermann M.R. Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J. Vet. Intern. Med. 2001, 15:516-529.
173. Rakhmilevich A.L. Neutrophils are essential for resolution of primary and secondary infection with Listeria monocytogenes. J. Leukoc. Biol. 1995, 57:827-831.
174. RansohoffR.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27:119-145.
175. Rapalino O., Lazarov-Spiegler O., Agranov E., Velan G.J., Yoles E., Fraidakis M., Solomon A., Gepstein R., Katz A., Belkin M., Hadani M., Schwartz M. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 1998, 4:814-821.
176. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 2005, 353:1711-1723.
177. Rigg J.L., Zafonte R.D. Corticosteroids in TBI: is the story closed?. J. Head Trauma Rehabil. 2006, 21:285-288.
178. Sadrzadeh S.M., Anderson D.K., Panter S.S., Hallaway P.E., Eaton J.W. Hemoglobin potentiates central nervous system damage. J. Clin. Invest. 1987, 79:662-664.
179. Saganova K., Orendacova J., Cizkova D., Vanicky I. Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. Neurosci. Lett. 2008, 433:246-249.
180. Saiwai H., Kumamaru H., Ohkawa Y., Kubota K., Kobayakawa K., Yamada H., Yokomizo T., Iwamoto Y., Okada S. Ly6C+Ly6G- Myeloid-derived suppressor cells play a critical role in the resolution of acute inflammation and the subsequent tissue repair process after spinal cord injury. J. Neurochem. 2013, 125:74-88.
181. Saiwai H., Ohkawa Y., Yamada H., Kumamaru H., Harada A., Okano H., Yokomizo T., Iwamoto Y., Okada S. The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Am. J. Pathol. 2010, 176:2352-2366.
182. Sanchez Mejia R.O., Ona V.O., Li M., Friedlander R.M. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001, 48:1393-1399. (discussion 1399-1401).
183. Saville L.R., Pospisil C.H., Mawhinney L.A., Bao F., Simedrea F.C., Peters A.A., O'Connell P.J., Weaver L.C., Dekaban G.A. A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment. J. Neuroimmunol. 2004, 156:42-57.
184. Scott G.S., Jakeman L.B., Stokes B.T., Szabo C. Peroxynitrite production and activation of poly (adenosine diphosphate-ribose) synthetase in spinal cord injury. Ann. Neurol. 1999, 45:120-124.
185. Shechter R., London A., Varol C., Raposo C., Cusimano M., Yovel G., Rolls A., Mack M., Pluchino S., Martino G., Jung S., Schwartz M. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med. 2009, 6:e1000113.
186. Short D.J., El Masry W.S., Jones P.W. High dose methylprednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspective. Spinal Cord 2000, 38:273-286.
187. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Springer, T. A., 1990. Adhesion receptors of the immune system. Nature 2012, 346:425-434.
188. Springer T.A. Adhesion receptors of the immune system. Nature. 1990 Aug 2, 346(6283):425-434.
189. Sroga J.M., Jones T.B., Kigerl K.A., McGaughy V.M., Popovich P.G. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J. Comp. Neurol. 2003, 462:223-240.
190. Stirling D.P., Cummins K., Mishra M., Teo W., Yong V.W., Stys P. Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury. Brain 2013 Dec 24, [Epub ahead of print]. 10.1093/brain/awt341.
191. Stirling D.P., Khodarahmi K., Liu J., McPhail L.T., McBride C.B., Steeves J.D., Ramer M.S., TetzlaffW. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 2004, 24:2182-2190.
192. Stirling D.P., Koochesfahani K.M., Steeves J.D., TetzlaffW. Minocycline as a neuroprotective agent. Neuroscientist 2005, 11:308-322.
193. Stirling D.P., Liu S., Kubes P., Yong V.W. Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. J. Neurosci. 2009, 29:753-764.
194. Stirling D.P., Yong V.W. Dynamics of the inflammatory response after murine spinal cord injury revealed by flow cytometry. J. Neurosci. Res. 2008, 86:1944-1958.
195. Stout R.D., Jiang C., Matta B., Tietzel I., Watkins S.K., Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 2005, 175:342-349.
196. Suberviola B., Gonzalez-Castro A., Llorca J., Ortiz-Melon F., Minambres E. Early complications of high-dose methylprednisolone in acute spinal cord injury patients. Injury 2008, 39:748-752.
197. Suk K. Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci. Lett. 2004, 366:167-171.
198. Sullivan P.G., Krishnamurthy S., Patel S.P., Pandya J.D., Rabchevsky A.G. Temporal characterization of mitochondrial bioenergetics after spinal cord injury. J. Neurotrauma 2007, 24:991-999.
199. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 2013, 13:739-752.
200. Taoka Y., Okajima K. Role of leukocytes in spinal cord injury in rats. J. Neurotrauma 2000, 17:219-229.
201. Taoka Y., Okajima K., Murakami K., Johno M., Naruo M. Role of neutrophil elastase in compression-induced spinal cord injury in rats. Brain Res. 1998, 799:264-269.
202. Taoka Y., Okajima K., Uchiba M., Murakami K., Kushimoto S., Johno M., Naruo M., Okabe H., Takatsuki K. Role of neutrophils in spinal cord injury in the rat. Neuroscience 1997, 79:1177-1182.
203. Teng Y.D., Choi H., Onario R.C., Zhu S., Desilets F.C., Lan S., Woodard E.J., Snyder E.Y., Eichler M.E., Friedlander R.M. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3071-3076.
204. Tepper R.I., Coffman R.L., Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992, 257:548-551.
205. Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 2001, 21:2580-2588.
206. Triarhou L.C., Herndon R.M. Effect of macrophage inactivation on the neuropathology of lysolecithin-induced demyelination. Br. J. Exp. Pathol. 1985, 66:293-301.
207. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 1994, 174:83-93.
208. van Rooijen N., Sanders A., van den Berg T.K. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J. Immunol. Methods 1996, 193:93-99.
209. Vestweber D. Novel insights into leukocyte extravasation. Curr. Opin. Hematol. 2012, 19:212-217.
210. Wang J., Wei Q., Wang C.Y., Hill W.D., Hess D.C., Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J. Biol. Chem. 2004, 279:19948-19954.
211. Wanner I.B., Anderson M.A., Song B., Levine J., Fernandez A., Gray-Thompson Z., Ao Y., Sofroniew M.V. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. J. Neurosci. 2013, 33:12870-12886.
212. Weaver L.C., Dekaban G.A., Brown A. Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury. Exp. Neurol. 2012, 233:612-614.
213. Weaver L.C., Gris D., Saville L.R., Oatway M.A., Chen Y., Marsh D.R., Hamilton E.F., Dekaban G.A. Methylprednisolone causes minimal improvement after spinal cord injury in rats, contrasting with benefits of an anti-integrin treatment. J. Neurotrauma 2005, 22:1375-1387.
214. Wells J.E., Hurlbert R.J., Fehlings M.G., Yong V.W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003, 126:1628-1637.
215. Wilson J.R., Arnold P.M., Singh A., Kalsi-Ryan S., Fehlings M.G. Clinical prediction model for acute inpatient complications after traumatic cervical spinal cord injury: a subanalysis from the Surgical Timing in Acute Spinal Cord Injury Study. J. Neurosurg. Spine 2012, 17:46-51.
216. Wisniewski H.M., Bloom B.R. Primary demyelination as a nonspecific consequence of a cell-mediated immune reaction. J. Exp. Med. 1975, 141:346-359.
217. Wu B., Matic D., Djogo N., Szpotowicz E., Schachner M., Jakovcevski I. Improved regeneration after spinal cord injury in mice lacking functional T- and B-lymphocytes. Exp. Neurol. 2012, 237:274-285.
218. Xiong Y., Rabchevsky A.G., Hall E.D. Role of peroxynitrite in secondary oxidative damage after spinal cord injury. J. Neurochem. 2007, 100:639-649.
219. Xu J., Kim G.M., Chen S., Yan P., Ahmed S.H., Ku G., Beckman J.S., Xu X.M., Hsu C.Y. iNOS and nitrotyrosine expression after spinal cord injury. J. Neurotrauma 2001, 18:523-532.
220. Yang S.C., Chung P.J., Ho C.M., Kuo C.Y., Hung M.F., Huang Y.T., Chang W.Y., Chang Y.W., Chan K.H., Hwang T.L. Propofol inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1. J. Immunol. 2013, 190:6511-6519.
221. Yin Y., Cui Q., Gilbert H.Y., Yang Y., Yang Z., Berlinicke C., Li Z., Zaverucha-do-Valle C., He H., Petkova V., Zack D.J., Benowitz L.I. Oncomodulin links inflammation to optic nerve regeneration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19587-19592.
222. Yin Y., Cui Q., Li Y., Irwin N., Fischer D., Harvey A.R., Benowitz L.I. Macrophage-derived factors stimulate optic nerve regeneration. J. Neurosci. 2003, 23:2284-2293.
223. Yin Y., Henzl M.T., Lorber B., Nakazawa T., Thomas T.T., Jiang F., Langer R., Benowitz L.I. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat. Neurosci. 2006, 9:843-852.
224. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
225. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15769-15774.
226. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13496-13500.
227. Yuen T.J., Johnson K.R., Miron V.E., Zhao C., Quandt J., Harrisingh M.C., Swire M., Williams A., McFarland H.F., Franklin R.J., Ffrench-Constant C. Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination. Brain 2013, 136:1035-1047.
228. Yune T.Y., Lee J.Y., Jung G.Y., Kim S.J., Jiang M.H., Kim Y.C., Oh Y.J., Markelonis G.J., Oh T.H. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci. 2007, 27:7751-7761.
229. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A.C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65:3044-3048.
230. Zhang B., Gensel J.C. Is neuroinflammation in the injured spinal cord different than in the brain? Examining intrinsic differences between the brain and spinal cord. Exp. Neurol. 2014, 258:112-120. (in this issue).
231. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.
232. Zimmerman B.J., Granger D.N. Reperfusion-induced leukocyte infiltration: role of elastase. Am. J. Physiol. 1990, 259:H390-H394.